Every 10-Q that Zentalis Pharmaceuticals, Inc. (ZNTL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZNTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZNTL filings page.
Zentalis Pharmaceuticals, Inc. is a clinical-stage oncology company focused on azenosertib (ZN-c3), a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The program’s DENALI Part 2 trial is designed to support a potential accelerated approval, with Phase 3 ASPENOVA as the confirmatory trial.
For the quarter ended June 30, 2026, Zentalis reported a net loss of $42,286 thousand, or $0.59 per share, compared with $26,874 thousand a year earlier. Research and development expenses rose to $35,163 thousand, driven by a $7.0 million milestone to Recurium and higher DENALI/ASPENOVA costs, while general and administrative expenses were $9,228 thousand. For the first six months of 2026, net loss was $77,638 thousand.
As of June 30, 2026, Zentalis held $174.6 million in cash, cash equivalents and marketable securities, total assets of $215.3 million, and stockholders’ equity of $143.6 million, with 71.7 million common shares outstanding as of August 3, 2026. The company states it believes its cash resources will fund operations into late 2027 while it advances azenosertib, which has Fast Track Designation in Cyclin E1-positive PROC.
Zentalis Pharmaceuticals reported a narrower quarterly loss while advancing its lead cancer drug azenosertib. For the three months ended March 31, 2026, net loss was $35.4 million (or $0.50 per share), compared with $48.3 million (or $0.67 per share) a year earlier, helped by lower restructuring and stock-based compensation expenses.
Research and development spending was $28.7 million, reflecting higher clinical and manufacturing costs as the DENALI and ASPENOVA trials progress, while general and administrative expenses declined to $9.1 million. Operating cash use was $33.0 million in the quarter.
Cash, cash equivalents and marketable debt securities totaled $211.8 million as of March 31, 2026, and management believes this will fund operations into late 2027. The company began Phase 3 ASPENOVA in Cyclin E1-positive platinum-resistant ovarian cancer, triggering a subsequent $7.0 million milestone payment under its Recurium license, and expects topline DENALI Part 2 data by year-end 2026.
Zentalis Pharmaceuticals (ZNTL) filed its Q3 2025 report, highlighting lower operating spend and a solid cash position while advancing azenosertib in ovarian cancer. The company reported a Q3 net loss of $26.7 million on operating expenses of $33.7 million, driven by R&D $23.0 million and G&A $10.8 million. Investment and other income contributed $7.0 million in the quarter.
Cash, cash equivalents and marketable securities totaled $280.7 million as of September 30, 2025, and management believes this will fund operations into late 2027. Year to date, the company recorded $7.8 million in restructuring charges tied to a roughly 40% workforce reduction. Shares outstanding were 72,250,779 as of November 1, 2025.
Development continues on azenosertib (WEE1 inhibitor) in Cyclin E1‑positive platinum‑resistant ovarian cancer. DENALI Part 2 is enrolling, with topline data anticipated by year end 2026, and a Phase 3 confirmatory study is planned to run concurrently with Part 2b. The company noted that the October 1, 2025 U.S. government shutdown could delay FDA and SEC timelines.